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Background: Asaronaldehyde (2, 4, 5-trimethoxybeznaldehyde) is an active component of Acorus gramineus
rhizome. This study aims to evaluate the anti-Candida efficacy of asaronaldehyde and its three structural isomers,
namely, 2, 3, 4-trimethoxybenzaldehyde, 3, 4, 5-trimethoxybenzaldehyde, and 2, 4, 6- trimethoxybenzaldehyde.
Methods: Susceptibility testing of test compounds was carried out using standard methodology (M27-A2) as per
clinical and laboratory standards institute guidelines. Minimum fungicidal concentration (MFC) was determined as
the lowest concentration of drug killing 99.9% of Candida cells. The effect on sterol profile was evaluated using the
ergosterol quantitation method. Effects on morphogenesis, adhesion and biofilm formation in C. albicans were
studied using germ-tube, adherence and biofilm formation assays respectively. Cytotoxicity of test compounds to
human RBCs was determined by hemolysis assay.
Results: 2, 4, 6-Trimethoxybenzaldehyde exhibited significant anti-Candida activity (P = 0.0412). Minimum inhibitory
concentration (MIC) and minimum fungicidal concentration (MFC) were established as 0.25 and 0.5 mg/mL,
respectively. All of the test compounds showed significant inhibition of hyphal form transition in yeast at MIC/2 and
MIC/4 values. 3, 4, 5-Trimethoxybenzaldehyde and 2, 4, 6-trimethoxybenzaldehyde inhibited adhesion and biofilms.
A hemolytic assay of these compounds revealed that they were non-toxic at MIC values. Asaronaldehyde reduced
sterol content.
Conclusion: Asaronaldehyde and 2, 4, 6-trimethoxybenzaldehyde showed anti-Candida efficacy.Background
Drug resistant pathogens and serious side effects are
major problems in antifungal chemotherapy [1]. Candida
species are the fourth leading cause of nosocomial blood-
stream infections in the United States, with treatment
costs estimated to be more than two to four billion US
dollars annually [2] and with attributable mortality rates
estimated to be 38–49% [3]. Candida albicans is a ubiqui-
tous organism in humans and causes serious disseminated
infections in the immunocompromised population [4]. It
colonizes and forms biofilms on host tissues and indwell-
ing prosthetic devices [5]. Biofilms are resistant to most
of the available antibiotics, except echinocandins (e.g.,
caspofungin and micafungin) [6]. Several antifungal com-
pounds have been developed, targeting diverse biological* Correspondence: prof.karuppayil@gmail.com
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reproduction in any medium, provided the orpathways essential for fungal growth, e.g., the ergosterol
synthesis pathway or its end product ergosterol [7]. Unfor-
tunately, most of the available antifungals have side effects,
such as nephrotoxicity (amphotericin B) and gastrointes-
tinal intolerance (Fluconazole), and drug resistance has
developed [8-10]. The emergence of drug resistance and
serious side effects suggest the need for new and safer
antifungals.
Chinese and Korean pharmacopoeias have demon-
strated sedative, digestive, analgesic, diuretic and anti-
fungal actions of extracts of Acorus gramineus [11-14].
Asaronaldehyde (2, 4, 5-trimethoxybeznaldehyde), an ac-
tive principle of A. gramineus rhizomes, exhibits fungi-
cidal activity against several phytopathogenic fungi [15].
Asaronaldehyde is a selective inhibitor of cyclooxygenase
II (COX-II) [16], consisting of a benzene ring substituted
with aldehyde and methoxy groups. Aromatic com-
pounds bearing a trimethoxy group are known to exhibitLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, structurally related compounds differ in their bio-
activities, and the difference in the conformation and
position of the functional group(s) determines their bind-
ing affinity to target molecules and clinical efficacy [18,19].
To our knowledge, the effects of asaronaldehyde and its
structural isomers, namely, 2, 3, 4-trimethoxybenzal-
dehyde, 3, 4, 5-trimethoxybenzaldehyde, and 2, 4, 6-
trimethoxybenzaldehyde (Figure 1), on the human
pathogenic yeast C. albicans, have not been reported.
However, alpha and beta asarones are known to exhibit
anti-C. albicans activity [20].
This study aimed to investigate the anti-Candida effi-
cacy and mechanism of action of asaronaldehyde and its
structural isomers.
Methods
Media, chemicals and culture conditions
The C. albicans ATCC 90028 (MTCC 3017) strain was
obtained from the Institute of Microbial Technology
(Chandigarh, India), and was maintained on Yeast–Pep-
tone–Dextrose (YPD) agar slants at 4°C. RPMI-1640
medium (with L-glutamine and without sodium bicarbon-
ate), 3-[N-morpholine] propane sulfonic acid (MOPS),
Sabourauds dextrose broth (SDB), YPD media and 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) were purchased from Hi-Media Laboratories Ltd.Figure 1 Chemical structures of A: 2,4,5-trimethoxybenzaldehyde,
B: 2,3,4- trimethoxybenzaldehyde, C: 3,4,5-trimethoxybenzaldehyde
and D: 2,4,6-trimethoxybenzaldehyde.(Mumbai, India). Triton-X 100 was purchased from
Qualigens Fine Chemicals Pvt. Ltd. (India). 2, 4, 5-Trime-
thoxybenzaldehyde (asaronaldehyde or asaraldehyde), 2, 3,
4-trimethoxybenzaldehyde, 3, 4, 5-trimethoxybenzal-
dehyde, and 2, 4, 6-trimethoxybenzaldehyde were pur-
chased from Thermo Fisher Scientific (Acros Organics),
Pvt. Ltd. (India).
Growth assay
The susceptibility study was carried out using the
microbroth dilution method as per clinical and labora-
tory standards institute (CLSI) guidelines [21]. Various
concentrations of the test compounds (0.0156 mg/mL to
8 mg/mL) were prepared in RPMI-1640 medium by
double dilution in 96-well plates. Each well contained an
inoculum of 1 × 103 cells mL-1 and the final volume of
RPMI-1640 medium maintained in each well was
200 μL. Wells without addition of compounds served as
a control. Microplates were incubated at 35°C for 48 h
and read spectrophotometrically at 620 nm using a
microplate reader (Multiskan EX, Thermo Electron
Corp. USA). The minimum inhibitory concentration
(MIC) was considered to be the minimum concentration
required to produce a 50% reduction in absorbance.
Viability assay
Cells from the MIC and the wells above were selected to
determine the minimum candidacidal concentrations of
the test compounds. An aliquot of 10 μL of cell suspen-
sion from each well was spread on YPD agar plates. The
plates were incubated for 24 h at 30°C and observed for
the presence of colonies. Minimum fungicidal concen-
tration (MFC) was considered as the lowest concentra-
tion required to kill 99.9% of Candida cells [22].
Hemolytic activity
The hemolytic activities of the test compounds were de-
termined using human red blood cells [23]. Human
erythrocytes from healthy persons were collected in
tubes containing EDTA (1–2 mg/ml) as anti-coagulant.
The erythrocytes were harvested by centrifugation
(Heraeus Megafuge 40, Thermo Fisher Scientific Inc.,
MA) for 10 min at 634 × g at 20°C, and washed three
times in PBS. PBS was added to the pellet to yield a 10%
(v/v) erythrocytes/PBS suspension. The 10% suspension
was diluted 1:10 in PBS. From each suspension, 100 μL
was added in triplicate to 100 μL of a different dilution
series of test compounds (or fluconazole as a standard
antifungal) in the same buffer in Eppendorf tubes. Total
hemolysis was achieved using 1% Triton X-100. The
tubes were incubated for 1 h at 37°C and centrifuged for
10 min at 634 × g at 20°C. From the supernatant fluid,
150 μL was transferred to a flat-bottomed microtiter
plate (Tarson India Ltd., India), and the absorbance was
Rajput et al. Chinese Medicine 2013, 8:18 Page 3 of 8
http://www.cmjournal.org/content/8/1/18measured at 450 nm. Percent hemolysis was calculated
using following equation:
%Hemolysis
¼ A450of test compound treated sample−A450of buffer treated sample
A450of 1 % Triton−X 100 treated sample−A450of buffer treated sampleÞ
 100 %
Ergosterol extraction and quantitation assay
A single colony of C. albicans from an overnight grown
SDA plate culture was used to inoculate 50 mL of SDB
containing various concentrations of different test com-
pounds. SDB without test compound served as a control.
The cultures were incubated for 16–18 h and harvested
by centrifugation at 856 × g for 5 min. The net weight of
the cell pellet was determined. Three milliliters of 25%
alcoholic potassium hydroxide solution was added to the
cell pellet and vortex mixed for 1 min. Cell suspensions
were transferred to sterile borosilicate glass screw-cap
tubes and incubated in an 85°C water bath for 1 h. Fol-
lowing incubation, the tubes were cooled. Sterols were
extracted by addition of a mixture of 1 mL of sterile dis-
tilled water and 3 mL of n-heptane followed by vigorous
vortex mixing for 3 min. The heptane layer was transferred
to a clean borosilicate glass screw-cap tube. Prior to ana-
lysis, a 0.6 mL aliquot of sterol extract was diluted five fold
in 100% ethanol and scanned between 240 and 300 nm
using a spectrophotometer (UV-1800 Spectrophotometer,
Shimadzu, Japan). Ergosterol content was calculated as a
percentage of the wet weight of the cell [24].
Germ tube formation assay
Inhibition of in vitro germ tube formation by test com-
pounds was studied using 96-well microtiter plates based
on the method of Chauhan et al. [25]. Cells were inocu-
lated in RPMI-1640 medium with various concentrations
of test compounds to obtain 1 × 106 cells/mL. Wells
without test compound were used as a control. The
plates were incubated at 37°C with shaking at 200 rpm
on an orbital shaker for 3 h, and cells were observed
microscopically. Each time, 100 cells were counted and
the numbers of yeast cells (budded or unbudded) and
germ tubes formed were noted. The percentage of germ
tube formation in each well compared with that in the
control well was calculated.
Adhesion assay
The effects of the four test compounds on adherence of
C. albicans to a polystyrene surface were studied based
on the method of Camacho et al. [26]. In brief, 1 ×
107 cells/mL was allowed to adhere to the polystyrene
surface of 96-well plates in the presence of various con-
centrations ranging from 0.0156 mg/mL to 2 mg/mL of
the test compounds in PBS. Wells without test compoundwere used as controls. The plates were incubated at 37°C
for 90 min at 100 rpm on an orbital shaking incubator to
allow cell attachment to the surface. After the incubation,
wells were washed with PBS to remove non-adhered cells.
The density of adherence in each well was analyzed using
an MTT metabolic assay and the percentage of adhered
cells was calculated and compared with that in control
wells. MTT solution was prepared by mixing 1 mg/mL
MTT salt in PBS and storing at −20°C.
Biofilm formation assay
C. albicans biofilms were developed on polystyrene
surfaces of 96-well plates as per standard methodolo-
gies [27]. One hundred microliters of a cell suspension
(1 × 107 cells/mL) in PBS was inoculated and plates
were incubated at 37°C for 90 min to allow attachment
of cells onto the surface. Non-adhered cells were re-
moved by washing the wells with sterile PBS, two to
three times. RPMI-1640 medium (200 μL) was added
to each well and the plates were incubated at 37°C for
24 h to allow biofilm formation. RPMI-1640 medium
with various concentrations of test compound was added
immediately after the adhesion phase to observe any ef-
fects on the development of biofilms. After incubation,
wells were washed to remove any released cells, and
biofilms were observed under an inverted light micro-
scope (Metzer, India). Biofilm growth was analyzed by
MTT-metabolic assay.
Biofilm quantitation by MTT assay
Biofilm growth was quantified by MTT metabolic assay
[27]. Wells containing biofilms were washed with PBS to
remove non adhered cells and incubated for 5 h in 100 μL
of MTT solution in the dark. After incubation, unbound
MTT was replaced with 150 μL of DMSO (100%) for 2 to
3 min. Treated samples (100 μL) were then taken into
new wells. Color formation was measured at 450 nm using
a microplate reader (Multiskan EX, Thermo Electron
Corp. USA). Wells without test compounds were used as
controls, while those without biofilms were the blanks.
Scanning electron microscopy (SEM) of C. albicans
biofilms
Candida biofilms were developed by seeding silicon discs
with 2 mL of standardized cell suspension of 1 × 107cells/
mL into 12-well plates. The plates were incubated at 37°C
at 50 rpm for 90 min. Non-adhered cells were removed by
washing the discs with PBS 2–3 times. RPMI-1640
medium along with 2, 4, 6-TMB (0.5 mg/mL) and one
control without 2, 4, 6-TMB was added to each well. The
final volume of the assay system in each well was kept to
3 mL. The plate was incubated at 37°C for 24 h to allow
biofilm formation. After incubation, discs were washed to
remove any planktonic cells. For SEM, samples were fixed
Figure 2 Effects of 2,4,5-trimethoxybenzaldehyde; 2,3,4-trimethoxybenzaldehyde; 3,4,5-trimethoxybenzaldehyde and
2,4,6-trimethoxybenzaldehyde on the growth of C. albicans ATCC 90028.
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(pH 7.2) for 24 h at 4°C. Samples were postfixed in a 2%
aqueous solution of osmium tetraoxide for 4 h, then
dehydrated in a series of graded alcohols and finally dried
to a critical drying point with a Critical Point Dryer unit.
The samples were mounted over stubs and gold coating
was performed by an automated gold coater (Model: JOEL
JFC-1600, JOEL Limited, Akishima, Tokyo 1960022, Japan)
for 3 min. Photos were taken under a scanning electronFigure 3 Effects of 2,4,5-trimethoxybenzaldehyde; 2,3,4-trimethoxybe
2,4,6-trimethoxybenzaldehyde on RPMI-1640-induced germ tube formmicroscope (Model: JOEL JSM 7600F, JOEL Limited,
Akishima, Tokyo 1960022, Japan) [25].
Statistical analysis
Values are presented as the means of triplicate observa-
tions ± standard deviation (SD). Percentage growth in
the presence of test compounds and in controls was
analyzed by Student’s t test (GraphPad prism 5.0 soft-
ware, USA), and P < 0.05 was considered statisticallynzaldehyde; 3,4,5-trimethoxybenzaldehyde and
ation in C. albicans ATCC 90028.
Figure 4 Germ tube formation of C. albicans ATCC 90028 in the absence of the test compound (A) and in the presence of an MIC/2
concentration of 2,4,5-trimethoxybenzaldehyde (B), 2,3,4-trimethoxybenzaldehyde (C), 3,4,5-trimethoxybenzaldehyde and (D)
2,4,6-trimethoxybenzaldehyde (E).
Figure 5 Effects of 2,4,5-trimethoxybenzaldehyde;
2,3,4-trimethoxybenzaldehyde; 3,4,5-trimethoxybenzaldehyde
and 2,4,6-trimethoxybenzaldehyde on adhesion in C. albicans
ATCC 90028.
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effect was visually determined.
Results and discussion
The compounds tested in this study, which differ only in
terms of the conformation or position of methoxy
groups, showed various degrees of antifungal activity.
All of the compounds significantly (P = 0.0412 for 2,
4, 5-trimethoxybenzaldehyde, P = 0.0454 for 2, 4,
5-trimethoxybenzaldehyde, P = 0.0490 for 2, 3, 4-
trimethoxybenzaldehyde, P = 0.0475 for 3, 4, 5-trime-
thoxybenzaldehyde) inhibited planktonic growth of
C. albicans in a concentration-dependent manner. 2, 4, 6-
trimethoxybenzaldehyde inhibited the growth and viability
of C. albicans at 0.25 and 1 mg/mL, respectively, while 2,
Figure 6 Effects of 2,4,5-trimethoxybenzaldehyde; 2,3,
4-trimethoxybenzaldehyde; 3,4,5-trimethoxybenzaldehyde and
2,4,6-trimethoxybenzaldehyde on biofilm formation in
C. albicans ATCC 90028.
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hyde and 3, 4, 5-trimethoxybenzaldehyde showed MIC at
1 mg/mL (Figure 2). The MFC of 2, 3, 4-trime-
thoxybenzaldehyde was 2 mg/mL, whereas the MFCs for
2, 4, 5-trimethoxybenzaldehyde and 3, 4, 5-trimetho-
xybenzaldehyde were 8 and 4 mg/mL, respectively.
Complete inhibition of Candida growth by the four com-
pounds was observed at sub-inhibitory concentrations
(Figure 3) (P = 0.0402 for 2, 4, 5-trimethoxybenzaldehyde,
P = 0.0410 for 2, 4, 5- trimethoxybenzaldehyde, P = 0.0480
for 2, 3, 4-trimethoxybenzaldehyde, and P = 0.0497 for 3,
4, 5-trimethoxybenzaldehyde). All four compounds
inhibited 80–100% of the yeast to hyphal transition at
sub-inhibitory concentrations (P = 0.0353 for 2, 4,
5-trimethoxybenzaldehyde, P = 0.0301 for 2, 4, 5-
trimethoxybenzaldehyde, P = 0.0390 for 2, 3, 4-tri-
methoxybenzaldehyde, and P = 0.0405 for 3, 4,
5-trimethoxybenzaldehyde). In addition to germ tube in-
hibition, inhibition of budding was also recorded (Figures 3
and 4). A greater than 50% of reduction in morphogenesisFigure 7 Scanning electron micrograph (at magnification × 2000) of a
2 × MIC of 2, 4, 6-trimethoxybenzaldehyde.was observed at 0.125 mg/mL for 2, 3, 4-trime-
thoxybenzaldehyde, 3, 4, 5-trimethoxybenzaldehyde and 2,
4, 6-trimethoxybenzaldehyde, while similar results were
observed at 0.25 mg/mL for 2, 4, 5-trimetho-
xybenzaldehyde. Inhibiting virulence factors, e.g., di-
morphism, without killing the pathogen, might avoid
natural selection and thereby prevent the emergence of a
drug-resistant population.
Adhesion is an early stage of biofilm development which
is important for Candida colonization and infection [5].
The compounds 3, 4, 5-trimethoxybenzaldehyde and 2, 4,
6-trimethoxybenzaldehyde significantly inhibited biofilm
development in C. albicans (P = 0.050 for 3, 4, 5-
trimethoxybenzaldehyde, and P = 0.0495 for 2, 4, 6-trime-
thoxybenzaldehyde) (Figures 5 and 6). These compounds
prevented more than 50% of adhesion at their MIC values
(P = 0.0481 for 3, 4, 5-trimethoxybenzaldehyde, and P =
0.0395 for 2, 4, 6-trimethoxybenzaldehyde). The com-
pound 2, 4, 5-trimethoxybenzaldehyde showed a 46%
reduction in adhesion at 1 mg/mL (P = 0.05). However,
2, 3, 4-trimethoxybenzaldehyde did not have a consider-
able effect on the adhesion of C. albicans yeast-phase
cells (P = 0.0481); only 19% inhibition of adhesion was
observed at MIC (Figure 5).
Biofilms are resistant to antifungal antibiotics, including
the most commonly prescribed drug, fluconazole [5,28].
All of the compounds tested significantly inhibited biofilm
formation, even at their MIC values. The MIC for preven-
tion of biofilm formation for 3, 4, 5-trimethoxy-benzalde-
hyde and 2, 4, 6-trimethoxybenzaldehyde was achieved at
the MIC for inhibition of growth (P = 0.05 for 3, 4,
5-trimethoxybenzaldehyde, and P = 0.0495 for 2, 4, 6-
trimethoxybenzaldehyde). Addition of 1 mg/mL 2, 4,
5-trimethoxybenzaldehyde and 2, 3, 4-trimethoxyben-
zaldehyde immediately after the adhesion phase caused
45% and 35% inhibition of biofilm formation, respectively
(P = 0.0377 for 2, 4, 5-trimethoxybenzaldehyde, andCandida albicans biofilm in the absence (A) and presence (B) of
Figure 8 Hemolysis caused by 2,4,5-trimethoxybenzaldehyde;
2,3,4-trimethoxybenzaldehyde; 3,4,5-trimethoxybenzaldehyde;
2,4,6-trimethoxybenzaldehyde and fluconazole.
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The ultrastructure of untreated C. albicans biofilms
exhibited a dense cell network of yeasts, budding yeasts
and hyphae. Treatment with 2, 4, 6-trimethoxyben-
zaldehyde significantly reduced cell density with few bud-
ded and hyphal forms (Figure 7).
The in vitro hemolytic assay is a screening tool for
gauging in vivo toxicity toward host cells [29]. The four
compounds tested showed no significant toxicity to hu-
man erythrocytes at minimum growth inhibitory concen-
trations (P = 0.0303 for 2, 4, 5-trimethoxybenzaldehyde,
P = 0.0331 for 2, 4, 5-trimethoxybenzaldehyde, P = 0.0396
for 2, 3, 4-trimethoxybenzaldehyde, and P = 0.040 for 3, 4,
5-trimethoxybenzaldehyde), whereas they had profound
effects on dimorphism, adhesion and biofilm formation by
C. albicans (Figure 8). Only 0–12% hemolysis was ob-
served at the tested concentrations, while fluconazole
showed 100% hemolysis at 0.5 mg/mL.
COX-dependent pathways may be responsible for the
prostaglandin (PGE2) synthesis in C. albicans, and prosta-
glandin induces pathogenicity in C. albicans [30,31].
COX-II inhibitors inhibit morphogenesis and biofilm for-
mation in C. albicans [32]. There is controversy about
whether COX inhibitors affect filamentation by blocking
prostaglandin synthesis and, moreover, it is known
that C. albicans does not encode a COX homolog.
Asaronaldehyde is a selective COX II inhibitor [33], andFigure 9 UV spectrophotometric sterol profile of C. albicans ATCC 900
0.25 (curve d), 0.5 (curve e) and 1 (curve f) mg/mL of asaronaldehydewas found to inhibit yeast to hyphal transition and biofilm
formation in this study.
In our study, asaronaldehyde inhibited sterol biosyn-
thesis. As shown in Figure 9, the average decreases in
total cellular ergosterol content of Candida cells after
exposure to their respective MIC, MIC/2, MIC/4,
MIC/8 and MIC/16 of 2, 4, 5-trimethoxybenzaldehyde
were 92%, 47%, 25%, 10% and 0% respectively (P =
0.0453 for 2, 4, 5-trimethoxybenzaldehyde, P = 0.0406
for 2, 4, 5-trimethoxybenzaldehyde, P = 0.0397 for 2, 3,
4-trimethoxybenzaldehyde, and P = 0.0485 for 3, 4,28, treated with 0 (curve a), 0.0625 (curve b), 0.125 (curve c),
(2,4,5- trimethoxybenzaldehyde).
Rajput et al. Chinese Medicine 2013, 8:18 Page 8 of 8
http://www.cmjournal.org/content/8/1/185-trimethoxybenzaldehyde). Other compounds did not
show any effect on ergosterol biosynthesis. Additionally,
beta-asarone, which is closely related to asaronaldehyde,
inhibits ergosterol biosynthesis in C. albicans [34].
Conclusion
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